MCID: CLS010
MIFTS: 44

Cluster Headache

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Cluster Headache

MalaCards integrated aliases for Cluster Headache:

Name: Cluster Headache 53 37 55 72

Classifications:



External Ids:

KEGG 37 H01588
ICD10 33 G44.0
UMLS 72 C0009088

Summaries for Cluster Headache

NIH Rare Diseases : 53 Cluster headaches are a form of headache notable for their extreme pain and their pattern of occurring in "clusters", usually at the same time(s) of the day for several weeks. The headaches are accompanied by autonomic symptoms, and some people experience restlessness and agitation. A cluster headache begins with severe pain strictly on one side of the head, often behind or around one eye. In some people, it may be preceded by a migraine-like "aura." The pain usually peaks over the next 5 to 10 minutes, and then continues at that intensity for up to three hours before going away. Typical attacks may strike up to eight times a day and are relatively short-lived. On average, a cluster period lasts 6 to 12 weeks. Autonomic symptoms may include: conjunctival injection (bloodshot eyes), swelling under or around the eye, excessive tearing of the eyes, drooping of the eyelid, runny nose and/or nasal congestion, and forehead and facial sweating. These symptoms generally occur only during the pain attack and are on the same side as the headache pain. Cluster headaches usually begin between the ages of 20 and 50, although they can start at any age. Males are more commonly affected than females. Treatment can be divided into acute therapy aimed at stopping symptoms once they have started and preventive therapy aimed at preventing recurrent attacks during the cluster period.

MalaCards based summary : Cluster Headache is related to migraine with or without aura 1 and familial hemiplegic migraine, and has symptoms including headache and recurrent paroxysmal headache. An important gene associated with Cluster Headache is HCRTR2 (Hypocretin Receptor 2), and among its related pathways/superpathways are Neuroscience and Myometrial Relaxation and Contraction Pathways. The drugs Betamethasone and Rizatriptan have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and hypothalamus.

KEGG : 37
Cluster headache (CH) is the commonest of the trigeminal autonomic cephalalgias (TAC) characterized by attacks of severe, strictly unilateral pain, which is orbital, supraorbital, temporal, or in any combination of these sites, with duration of pain attacks of 15 to 180 min. The pain of CH is associated with ipsilateral conjunctival injection, lacrimation, nasal congestion, rhinorrhea, forehead and facial sweating, miosis, ptosis and/or eyelid edema, and/or restlessness or agitation. Headaches often recur at the same time each day during the cluster period, which can last for weeks to months. CH occurs more commonly in male patients (2.5:1 to 4.3:1 male to female) with an average age of onset in the third or fourth decade. The pathophysiology of CH is not fully understood, but may include a genetic component. Treatment focuses on avoiding triggers and includes abortive therapies, prophylaxis during the cluster period, and long-term treatment in patients with chronic CH. Evidence supports the use of supplemental oxygen, sumatriptan, and zolmitriptan for acute treatment of episodic CH. Verapamil is used to treat chronic CH. More invasive treatments, including nerve stimulation and surgery, may be helpful in refractory cases.

Wikipedia : 75 Cluster headache (CH) is a neurological disorder characterized by recurrent severe headaches on one side... more...

Related Diseases for Cluster Headache

Diseases in the Cluster Headache family:

Cluster Headache, Familial

Diseases related to Cluster Headache via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 migraine with or without aura 1 30.3 VIP CALCA CACNA1A ADCYAP1
2 familial hemiplegic migraine 30.1 CALCA CACNA1A
3 hemiplegic migraine 30.1 CALCA CACNA1A
4 constipation 29.5 VIP CALCA
5 cluster headache, familial 12.8
6 headache 11.9
7 paroxysmal hemicrania 11.8
8 hemicrania continua 11.1
9 trigeminal neuralgia 10.5
10 ptosis 10.4
11 migraine without aura 10.4
12 horner's syndrome 10.4
13 sleep apnea 10.3
14 migraine with aura 10.3
15 autonomic dysfunction 10.3
16 trigeminal autonomic cephalalgia 10.2
17 carotid artery dissection 10.2
18 head injury 10.2
19 wdha syndrome 10.2 VIP CALCA
20 meningioma, radiation-induced 10.2
21 meningioma, familial 10.2
22 spinal meningioma 10.2
23 secretory meningioma 10.2
24 lymphoplasmacyte-rich meningioma 10.2
25 leprosy 2 10.2 VIP CALCA
26 vasomotor rhinitis 10.2 VIP CALCA
27 pancreatic cholera 10.2 VIP CALCA
28 chronic pain 10.2
29 somatostatinoma 10.1 VIP CALCA
30 diffuse pulmonary fibrosis 10.1 VIP CALCA
31 rare surgical neurologic disease 10.1
32 islet cell tumor 10.1 VIP CALCA
33 angina pectoris 10.1
34 arteriovenous malformation 10.1
35 peptic ulcer disease 10.1
36 rare headache 10.1
37 hemiplegia 10.1 CALCA CACNA1A
38 anisocoria 10.0
39 myositis 10.0
40 kearns-sayre syndrome 10.0
41 anxiety 10.0
42 tolosa-hunt syndrome 10.0
43 sleep disorder 10.0
44 cerebrovascular disease 10.0
45 orbital plasma cell granuloma 10.0
46 sunct headache 10.0
47 paresthesia 10.0
48 syncope 10.0
49 tremor 10.0
50 alternating hemiplegia of childhood 10.0 CALCA CACNA1A

Graphical network of the top 20 diseases related to Cluster Headache:



Diseases related to Cluster Headache

Symptoms & Phenotypes for Cluster Headache

UMLS symptoms related to Cluster Headache:


headache, recurrent paroxysmal headache

Drugs & Therapeutics for Cluster Headache

Drugs for Cluster Headache (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
2
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Ethanol Approved Phase 4 64-17-5 702
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
11
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
13
Topiramate Approved Phase 4 97240-79-4 5284627
14
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
15 Oxazolidinones Phase 4
16 Anti-Infective Agents Phase 4
17 Betamethasone-17,21-dipropionate Phase 4
18 Betamethasone Valerate Phase 4 2152-44-5
19 Betamethasone sodium phosphate Phase 4
20 Betamethasone benzoate Phase 4
21 Serotonin Receptor Agonists Phase 4
22 Neurotransmitter Agents Phase 4
23 Serotonin Agents Phase 4
24 Peripheral Nervous System Agents Phase 4
25 Immunologic Factors Phase 4
26 Gastrointestinal Agents Phase 4
27 Antiemetics Phase 4
28 Autonomic Agents Phase 4
29 triamcinolone acetonide Phase 4
30 Triamcinolone hexacetonide Phase 4
31 Triamcinolone diacetate Phase 4
32 Anesthetics, Local Phase 4
33 Anesthetics Phase 4
34 HIV Protease Inhibitors Phase 4
35
protease inhibitors Phase 4
36 Central Nervous System Depressants Phase 4
37 Immunosuppressive Agents Phase 4
38 BB 1101 Phase 4
39 Sodium Channel Blockers Phase 4
40 Diuretics, Potassium Sparing Phase 4
41 Hormone Antagonists Phase 4
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
43 Anti-Inflammatory Agents Phase 4
44 Neuroprotective Agents Phase 4
45 glucocorticoids Phase 4
46 Methylprednisolone Acetate Phase 4
47 Protective Agents Phase 4
48 Antineoplastic Agents, Hormonal Phase 4
49 Prednisolone acetate Phase 4
50 Hypoglycemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Zolmitriptan by Sublingual Administration in the Treatment of Cluster Headache: A Multi-center Randomized Cross-controlled Trial Unknown status NCT03377257 Phase 4 zolmitriptan by sublingual administration;zolmitriptan by oral
2 4mg StatDose Imitrex for Acute Treatment of Cluster Headache Unknown status NCT00399243 Phase 4 Sumatriptan 4mg Statdose injection
3 Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study Unknown status NCT02686983 Phase 4 Betamethasone and local anesthetic
4 A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms. Completed NCT00753311 Phase 4 rizatriptan or placebo
5 Greater Occipital Nerve Block for Migraine Prophylaxis Completed NCT00915473 Phase 4 bupivicaine;normal saline;methylprednisolone;lidocaine
6 A Comparison of Dexamethasone and Triamcinolone in Combination With Bupivacaine for Ultrasound-guided Occipital C2 Nerve Blocks: A Randomized Controlled Trial Recruiting NCT02655523 Phase 4 Triamcinolone;Dexamethasone;Normal Saline;Bupivacaine
7 A Phase IV Single Blind Placebo-controlled Cross Over Study to Investigate the Efficacy of Greater Occipital Nerve Block With Local Anesthetic and Steroid in Patients With Chronic Migraine Recruiting NCT04017741 Phase 4 Combined Depo-Medrone and Lidocaine;Sodium Chloride 0.9% Inj
8 GON-injection for a Sooner and Better Treatment of Cluster Headache: a Double-blind Randomized Controlled Trial Not yet recruiting NCT04014634 Phase 4 Methylprednisolone
9 A Single-Center, Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Topiramate in the Treatment of Subjects With Episodic or Chronic Cluster Headache. Terminated NCT00203190 Phase 4 Topiramate
10 Safety and Efficacy of Sodium Oxybate in the Prophylaxis of Headache and Sleep Disturbances in Patients With Chronic and Episodic Cluster Headache Unknown status NCT02637648 Phase 3 Sodium Oxybate;Placebo
11 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache Completed NCT00033839 Phase 3 Civamide (Zucapsaicin)
12 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache Completed NCT02397473 Phase 3 Galcanezumab;Placebo
13 A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache Completed NCT02964338 Phase 3 Fremanezumab- A;Fremanezumab- B;Placebo
14 Imigran STATdose - Japan Clinical Experience Study for Self-injection Completed NCT00356603 Phase 3 Sumatriptan Succinate
15 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache Completed NCT00069082 Phase 3 Civamide (Zucapsaicin);Sodium Chloride
16 A Double Blind Randomized Controlled Trial of Greater Occipital Nerve Infiltration in Cluster Headache Completed NCT00804895 Phase 2, Phase 3 ALTIM, cortivazol injections;PROAMP, subcutaneous serum physiological saline;Verapamil
17 Anodal Transcranial Direct Stimulation (tDCS) of the Anterior Cingulate Gyrus for the Treatment of Chronic Cluster Headache: a Pilot Trial. Completed NCT02462395 Phase 2, Phase 3
18 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache Active, not recruiting NCT02438826 Phase 3 Galcanezumab 300 mg;Placebo
19 Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache Active, not recruiting NCT01151631 Phase 3
20 A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache Enrolling by invitation NCT02797951 Phase 3 Galcanezumab
21 A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Headache Period Not yet recruiting NCT01341548 Phase 3 Civamide nasal solution 0.01%
22 Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Not yet recruiting NCT03944876 Phase 3 Botulinum toxin type A;placebo
23 Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches Not yet recruiting NCT04066023 Phase 2, Phase 3 C213 Microneedle System;Placebo
24 A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Epidosic Cluster Headache Terminated NCT02945046 Phase 3 Fremanezumab - A;Fremanezumab - B;Placebo
25 A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache Terminated NCT03107052 Phase 3 Fremanezumab
26 Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache Unknown status NCT00274170 Phase 1, Phase 2 Octreotide
27 Endoscopic Block of the Sphenopalatine Ganglion With Botulinum Toxin in Intractable Cluster Headache - Safety Issues Completed NCT02019017 Phase 1, Phase 2 Botulinum Toxin Type A 25 IU;Botulinum Toxin Type A 50 IU
28 Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study Completed NCT00184587 Phase 2 candesartan cilexetil;placebo
29 A Randomized, Multicenter Study for the Prevention and Acute Treatment of Chronic Cluster Headache Using Gammacore, Versus Standard of Care. Completed NCT01701245 Phase 2
30 Multicenter Feasibility Study of the Bion for Occipital Nerve Stimulation for Treatment of Chronic Headaches Completed NCT00205894 Phase 1, Phase 2
31 Safety and Efficacy of Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache: a Randomized, Double-blind, Placebo-controlled Phase II Study Recruiting NCT03781128 Phase 2 Lysergic Acid Diethylamide;Placebo
32 Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues Recruiting NCT03066635 Phase 1, Phase 2 Botulinum Toxin Type A 25 IU;Botulinum Toxin Type A 12.5 IU
33 A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 Subcutaneous (s.c.) Terminated NCT02619617 Phase 2 SOM230;Placebo
34 A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prophylaxis of Episodic Cluster Headache Terminated NCT02209155 Phase 2 R-verapamil 75 mg tablet;Placebo
35 An Open Label, Pilot Study Evaluating the Efficacy and Safety of the Use of Nasal Carbon Dioxide for the Treatment of Episodic Cluster Headache Terminated NCT02381795 Phase 2 Nasal Carbon Dioxide
36 Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders Recruiting NCT02981173 Phase 1 0.143 mg/kg Psilocybin;0.0143 mg/kg Psilocybin;Placebo
37 The Pain Biomarker Study: Changes in Circulating Pain Signalling Molecules With Activation of Pain Receptors Active, not recruiting NCT03511846 Phase 1 Oral capsaicin;Topical capsaicin;Intranasal capsaicin;Low Flow Oxygen;High Flow Oxygen
38 A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache Terminated NCT01298921 Phase 1 Oxygen;Oxygen
39 Effectiveness of Physiotherapy Program in Patients With Cluster Headache Unknown status NCT02460003
40 Study of the Cerebral Metabolism in Patients With Refractory Chronic Cluster Headache Treated by Occipital Nerve Stimulation Unknown status NCT02081482
41 Cluster Headache (CH), Addictions and Vascular Function Unknown status NCT02640105
42 French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders Unknown status NCT01842763
43 DBS of the Third Ventricle for Cluster Headache and Obesity Completed NCT02782533
44 Sleep in Cluster Headache: Sleep Parameters in- and Outside a Cluster Bout Completed NCT03439722
45 Long-Term Follow-Up for the Pathway CH-1 Trial: Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache Completed NCT01616511
46 Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache Completed NCT01255813
47 Administration of Oxygen to Cluster Headache Patients Completed NCT01589588
48 Circadian Rhythm and Attack-timing in Episodic Cluster Headache Patients in- and Outside of Bout: an Actigraphic Study Completed NCT02853487
49 A Research Study to Examine Cutaneous Allodynia and Cluster Headache Completed NCT00329836
50 Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache Completed NCT01677026

Search NIH Clinical Center for Cluster Headache

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cyproheptadine
Cyproheptadine hydrochloride
CYPROHEPTADINE HYDROCHLORIDE MONOHYDRATE
Dihydroergotamine
Dihydroergotamine
ergoloid mesylates, USP
Ergotamine
Ergotamine
Oxygen
Sumatriptan
Sumatriptan Succinate
Topiramate

Genetic Tests for Cluster Headache

Anatomical Context for Cluster Headache

MalaCards organs/tissues related to Cluster Headache:

41
Brain, Eye, Hypothalamus, Testes, Pituitary, Heart, Spinal Cord

Publications for Cluster Headache

Articles related to Cluster Headache:

(show top 50) (show all 2765)
# Title Authors PMID Year
1
Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. 9 38
19330286 2009
2
Haplotype analysis confirms the association between the HCRTR2 gene and cluster headache. 9 38
18399985 2008
3
Investigation of neuromuscular transmission in some rare types of migraine. 9 38
17919307 2007
4
Association between migraine and the G1246A polymorphism in the hypocretin receptor 2 gene. 9 38
17883525 2007
5
CGRP-receptor antagonism in migraine treatment. 9 38
17691979 2007
6
Association between the G1246A polymorphism of the hypocretin receptor 2 gene and cluster headache: a meta-analysis. 9 38
17563843 2007
7
The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. 9 38
17376114 2007
8
Serotonin receptor ligands: treatments of acute migraine and cluster headache. 9 38
17087122 2007
9
Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene. 9 38
16554494 2006
10
Neurobiology in primary headaches. 9 38
15914251 2005
11
New targets in the acute treatment of headache. 9 38
15891413 2005
12
Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. 9 38
16392873 2005
13
Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. 9 38
15867953 2005
14
A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. 9 38
15477554 2004
15
Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. 9 38
15265049 2004
16
Circulating nociceptin levels during the cluster headache period. 9 38
15030536 2004
17
New therapeutic target in primary headaches - blocking theCGRP receptor. 9 38
12783573 2003
18
Calcitonin gene-related peptide (CGRP) in cerebrovascular disease. 9 38
12805934 2002
19
CACNA1A gene polymorphisms in cluster headache. 9 38
11843866 2001
20
No involvement of the calcium channel gene (CACNA1A) in a family with cluster headache. 9 38
11843867 2001
21
No involvement of the calcium channel gene (CACNA1A) in a family with cluster headache. 9 38
11843863 2001
22
[Both neurogenic and vascular causes of primary headache]. 9 38
11680150 2001
23
Sensory nerves in man and their role in primary headaches. 9 38
11595008 2001
24
Pathophysiology of primary headaches. 9 38
11252141 2001
25
Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. 9 38
11087777 2000
26
A pathophysiological view of primary headaches. 9 38
11200801 2000
27
A possible role for saliva as a diagnostic fluid in patients with chronic pain. 9 38
9662753 1998
28
Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients. 9 38
9117375 1997
29
Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. 9 38
7540279 1995
30
Neuropeptides in the cerebral circulation: relevance to headache. 9 38
7585922 1995
31
Neuropeptides in migraine and cluster headache. 9 38
7828188 1994
32
Nostril capsaicin application as a model of trigeminal primary sensory neuronal activation. 9 38
7520365 1994
33
Prevalence of headache attributed to aeroplane travel in headache outpatient populations: An Italian multicentric survey. 38
30961369 2019
34
Genetics of cluster headache. 38
30917683 2019
35
Increased suicidality in patients with cluster headache. 38
31018651 2019
36
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. 38
31424490 2019
37
[Neuromodulation in primary headache in the year 2019: is it still up-to-date? : New data on invasive and non-invasive neuromodulation in migraine and cluster headaches]. 38
31367955 2019
38
Facial presentations of migraine, TACs, and other paroxysmal facial pain syndromes. 38
31434691 2019
39
Ventral tegmental area deep brain stimulation for chronic cluster headache: Effects on cognition, mood, pain report behaviour and quality of life. 38
30897944 2019
40
The spectrum of cluster headache: A case report of 4600 attacks. 38
30913909 2019
41
Hypothalamic activation discriminates painful and non-painful initiation of the trigeminal autonomic reflex - an fMRI study. 38
31382763 2019
42
Differences in Characteristics and Comorbidity of Cluster Headache According to the Presence of Migraine. 38
31286705 2019
43
Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. 38
30824632 2019
44
Burst Occipital Nerve Stimulation for Chronic Migraine and Chronic Cluster Headache. 38
31199547 2019
45
Neuromodulation for the Acute and Preventive Therapy of Migraine and Cluster Headache. 38
31291017 2019
46
Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. 38
31291020 2019
47
Trial of Galcanezumab in Prevention of Episodic Cluster Headache. 38
31291515 2019
48
Anoctamin 3: A Possible Link between Cluster Headache and Ca2+ Signaling. 38
31366133 2019
49
Diagnostic delay of cluster headache: A cohort study from the Danish Cluster Headache Survey. 38
31291778 2019
50
Case report: Orbital myositis triggering oxygen-responsive cluster headache. 38
31345050 2019

Variations for Cluster Headache

Expression for Cluster Headache

Search GEO for disease gene expression data for Cluster Headache.

Pathways for Cluster Headache

GO Terms for Cluster Headache

Cellular components related to Cluster Headache according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.8 VIP GNB3 ADCYAP1
2 terminal bouton GO:0043195 8.65 ADCYAP1

Biological processes related to Cluster Headache according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.72 VIP HCRTR2 GNB3 CALCA ADCYAP1
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.54 CALCA CACNA1A ADCYAP1
3 regulation of insulin secretion GO:0050796 9.52 CLOCK CACNA1A
4 regulation of blood pressure GO:0008217 9.51 GNB3 CALCA
5 regulation of protein localization GO:0032880 9.49 VIP ADCYAP1
6 regulation of cytosolic calcium ion concentration GO:0051480 9.48 HCRTR2 CALCA
7 activation of adenylate cyclase activity GO:0007190 9.43 CALCA ADCYAP1
8 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.33 VIP CALCA ADCYAP1
9 negative regulation of potassium ion transport GO:0043267 9.26 VIP ADCYAP1
10 feeding behavior GO:0007631 9.16 HCRTR2
11 response to pain GO:0048265 9.1 CACNA1A
12 neuropeptide signaling pathway GO:0007218 8.96 HCRTR2 ADCYAP1
13 positive regulation of blood vessel diameter GO:0097755 8.8 VIP CALCA ADCYAP1

Molecular functions related to Cluster Headache according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.16 VIP ADCYAP1
2 peptide hormone receptor binding GO:0051428 8.96 VIP ADCYAP1
3 hormone activity GO:0005179 8.8 VIP CALCA ADCYAP1

Sources for Cluster Headache

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....